Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Autor:	Saagar N. Patel, Mona L. Camacci, Esther M. Bowie
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	fibroblast growth factor receptor fibroblast growth factor receptor retinopathy optical coherence tomography mitogen-activated protein kinase mitogen-activated protein kinase kinase associated retinopathy Ophthalmology RE1-994
Zdroj:	Case Reports in Ophthalmology, Vol 13, Iss 1, Pp 57-63 (2022)
Druh dokumentu:	article
ISSN:	1663-2699
DOI:	10.1159/000519275
Popis:	We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/0cb682218e264c76b6d0723877abd2a8 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.